Lifevantage (LFVN) Competitors

$5.22 +0.03 (+0.58%)

As of 03:36 PM Eastern

LFVN vs. ELDN, AVXL, ALXO, AKBA, and CGEN

Should you buy Lifevantage stock or one of its competitors? MarketBeat compares Lifevantage with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lifevantage include Eledon Pharmaceuticals (ELDN), Anavex Life Sciences (AVXL), ALX Oncology (ALXO), Akebia Therapeutics (AKBA), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry.

How does Lifevantage compare to Eledon Pharmaceuticals?

Lifevantage (NASDAQ:LFVN) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Eledon Pharmaceuticals had 2 more articles in the media than Lifevantage. MarketBeat recorded 4 mentions for Eledon Pharmaceuticals and 2 mentions for Lifevantage. Lifevantage's average media sentiment score of -0.44 beat Eledon Pharmaceuticals' score of -0.84 indicating that Lifevantage is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifevantage	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Lifevantage has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.29	$9.81M	$0.45	11.60
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A

Lifevantage presently has a consensus price target of $5.00, indicating a potential downside of 4.21%. Eledon Pharmaceuticals has a consensus price target of $9.67, indicating a potential upside of 169.64%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Lifevantage has a net margin of 2.94% compared to Eledon Pharmaceuticals' net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%

Lifevantage has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Summary

Lifevantage beats Eledon Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Lifevantage compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Anavex Life Sciences has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Lifevantage has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

Lifevantage has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
Lifevantage	$228.53M	0.29	$9.81M	$0.45	11.60

Lifevantage has a net margin of 2.94% compared to Anavex Life Sciences' net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
Lifevantage	2.94%	23.89%	12.47%

In the previous week, Anavex Life Sciences and Anavex Life Sciences both had 2 articles in the media. Anavex Life Sciences' average media sentiment score of 0.00 beat Lifevantage's score of -0.44 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifevantage	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 35.3% of Lifevantage shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by company insiders. Comparatively, 22.0% of Lifevantage shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Anavex Life Sciences presently has a consensus target price of $21.33, suggesting a potential upside of 683.45%. Lifevantage has a consensus target price of $5.00, suggesting a potential downside of 4.21%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Anavex Life Sciences is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lifevantage beats Anavex Life Sciences on 9 of the 14 factors compared between the two stocks.

How does Lifevantage compare to ALX Oncology?

Lifevantage (NASDAQ:LFVN) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Lifevantage presently has a consensus target price of $5.00, suggesting a potential downside of 4.21%. ALX Oncology has a consensus target price of $4.60, suggesting a potential upside of 136.14%. Given ALX Oncology's stronger consensus rating and higher probable upside, analysts clearly believe ALX Oncology is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Lifevantage has a net margin of 2.94% compared to ALX Oncology's net margin of 0.00%. Lifevantage's return on equity of 23.89% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
ALX Oncology	N/A	-124.06%	-85.57%

In the previous week, ALX Oncology had 11 more articles in the media than Lifevantage. MarketBeat recorded 13 mentions for ALX Oncology and 2 mentions for Lifevantage. ALX Oncology's average media sentiment score of 1.11 beat Lifevantage's score of -0.44 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifevantage	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifevantage has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.29	$9.81M	$0.45	11.60
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by insiders. Comparatively, 21.0% of ALX Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lifevantage has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

Summary

Lifevantage beats ALX Oncology on 9 of the 15 factors compared between the two stocks.

How does Lifevantage compare to Akebia Therapeutics?

Lifevantage (NASDAQ:LFVN) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, Lifevantage had 1 more articles in the media than Akebia Therapeutics. MarketBeat recorded 2 mentions for Lifevantage and 1 mentions for Akebia Therapeutics. Lifevantage's average media sentiment score of -0.44 beat Akebia Therapeutics' score of -0.83 indicating that Lifevantage is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifevantage	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akebia Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Lifevantage has a net margin of 2.94% compared to Akebia Therapeutics' net margin of -8.83%. Lifevantage's return on equity of 23.89% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

Lifevantage has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Lifevantage presently has a consensus price target of $5.00, suggesting a potential downside of 4.21%. Akebia Therapeutics has a consensus price target of $4.67, suggesting a potential upside of 424.93%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

35.3% of Lifevantage shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 22.0% of Lifevantage shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lifevantage has higher earnings, but lower revenue than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.29	$9.81M	$0.45	11.60
Akebia Therapeutics	$236.20M	1.01	-$5.34M	-$0.08	N/A

Summary

Lifevantage beats Akebia Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Lifevantage compare to Compugen?

Compugen (NASDAQ:CGEN) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Compugen presently has a consensus target price of $5.00, indicating a potential upside of 85.53%. Lifevantage has a consensus target price of $5.00, indicating a potential downside of 4.21%. Given Compugen's stronger consensus rating and higher probable upside, analysts clearly believe Compugen is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

12.2% of Compugen shares are owned by institutional investors. Comparatively, 35.3% of Lifevantage shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 22.0% of Lifevantage shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Compugen had 3 more articles in the media than Lifevantage. MarketBeat recorded 5 mentions for Compugen and 2 mentions for Lifevantage. Lifevantage's average media sentiment score of -0.44 beat Compugen's score of -0.57 indicating that Lifevantage is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Lifevantage	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compugen has a net margin of 48.57% compared to Lifevantage's net margin of 2.94%. Compugen's return on equity of 55.68% beat Lifevantage's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	48.57%	55.68%	29.68%
Lifevantage	2.94%	23.89%	12.47%

Compugen has a beta of 2.79, indicating that its stock price is 179% more volatile than the broader market. Comparatively, Lifevantage has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

Compugen has higher earnings, but lower revenue than Lifevantage. Compugen is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	3.50	$35.34M	$0.37	7.28
Lifevantage	$228.53M	0.29	$9.81M	$0.45	11.60

Summary

Compugen beats Lifevantage on 11 of the 17 factors compared between the two stocks.

Get Lifevantage News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFVN vs. The Competition

Export

Metric	Lifevantage	MED/DENTAL Industry	Medical Sector	NASDAQ Exchange
Market Cap	$65.94M	$14.43B	$6.27B	$12.13B
Dividend Yield	3.48%	2.12%	2.80%	5.32%
P/E Ratio	11.61	15.91	20.61	25.11
Price / Sales	0.29	2.08	578.26	91.48
Price / Cash	4.70	12.77	27.48	37.30
Price / Book	1.90	3.09	9.72	6.63
Net Income	$9.81M	$534.24M	$3.55B	$335.73M
7 Day Performance	1.36%	4.73%	-1.89%	-1.80%
1 Month Performance	9.21%	-0.61%	-3.77%	-1.69%
1 Year Performance	-60.39%	-6.03%	29.58%	27.59%

Lifevantage Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFVN Lifevantage	2.5916 of 5 stars	$5.22 +0.6%	$5.00 -4.2%	-61.2%	$65.94M	$228.53M	11.61	260
ELDN Eledon Pharmaceuticals	1.8299 of 5 stars	$3.48 -2.9%	$9.67 +178.2%	+24.7%	$265.77M	N/A	N/A	10	Earnings Report Analyst Downgrade
AVXL Anavex Life Sciences	1.5183 of 5 stars	$2.88 -0.2%	$21.33 +642.0%	-65.4%	$264.48M	N/A	N/A	40
ALXO ALX Oncology	3.8923 of 5 stars	$1.99 -0.8%	$4.60 +131.7%	+357.2%	$264.41M	N/A	N/A	40
AKBA Akebia Therapeutics	2.1605 of 5 stars	$0.99 -2.0%	$4.67 +371.4%	-61.3%	$263.70M	$236.20M	N/A	430	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFVN) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lifevantage (LFVN) Competitors

LFVN vs. ELDN, AVXL, ALXO, AKBA, and CGEN

How does Lifevantage compare to Eledon Pharmaceuticals?

Summary

How does Lifevantage compare to Anavex Life Sciences?

Summary

How does Lifevantage compare to ALX Oncology?

Summary

How does Lifevantage compare to Akebia Therapeutics?

Summary

How does Lifevantage compare to Compugen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFVN vs. The Competition

Lifevantage Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lifevantage (LFVN) Competitors

LFVN vs. ELDN, AVXL, ALXO, AKBA, and CGEN

How does Lifevantage compare to Eledon Pharmaceuticals?

Do insiders and institutionals have more ownership in LFVN or ELDN?

Does the media prefer LFVN or ELDN?

Which has stronger valuation & earnings, LFVN or ELDN?

Do analysts prefer LFVN or ELDN?

Is LFVN or ELDN more profitable?

Which has more risk & volatility, LFVN or ELDN?

Summary

How does Lifevantage compare to Anavex Life Sciences?

Which has more volatility and risk, AVXL or LFVN?

Which has higher earnings & valuation, AVXL or LFVN?

Is AVXL or LFVN more profitable?

Does the media prefer AVXL or LFVN?

Do institutionals and insiders hold more shares of AVXL or LFVN?

Do analysts prefer AVXL or LFVN?

Summary

How does Lifevantage compare to ALX Oncology?

Do analysts prefer LFVN or ALXO?

Is LFVN or ALXO more profitable?

Does the media refer more to LFVN or ALXO?

Which has higher valuation & earnings, LFVN or ALXO?

Do institutionals & insiders have more ownership in LFVN or ALXO?

Which has more volatility & risk, LFVN or ALXO?

Summary

How does Lifevantage compare to Akebia Therapeutics?

Does the media refer more to LFVN or AKBA?

Is LFVN or AKBA more profitable?

Which has more risk & volatility, LFVN or AKBA?

Do analysts recommend LFVN or AKBA?

Do insiders & institutionals have more ownership in LFVN or AKBA?

Which has higher earnings & valuation, LFVN or AKBA?

Summary

How does Lifevantage compare to Compugen?

Do analysts rate CGEN or LFVN?

Do institutionals & insiders believe in CGEN or LFVN?

Does the media refer more to CGEN or LFVN?

Is CGEN or LFVN more profitable?

Which has more risk & volatility, CGEN or LFVN?

Which has stronger valuation and earnings, CGEN or LFVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFVN vs. The Competition

Lifevantage Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools